Aptus Pharma
add_icon

Aptus Pharma

156.00
+0.15
(0.10%)
Market Cap
₹- Cr
PE Ratio
-
Volume
12,000.00
Day High - Low
₹157.00 - ₹155.80
52W High-Low
₹168.35 - ₹80.80
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
- Cr
EPS
-
PB Ratio
-
Book Value
29.13
EBITDA
-
Dividend Yield
- %
ROE Growth %
-
Debt to Equity
-
Forecast For
Actual

Company News

View All News
Caret
positive
Aptus Pharma has launched a new urology therapy segment as part of its business expansion strategy. The company aims to use this new therapeutic area to drive revenue growth and diversify its pharmaceutical portfolio.
positive
Aptus Pharma Limited announced financial results for the half-year ended September 30, 2025. The company reported revenue of Rs. 1,437.75 lakhs, representing 47.38% year-over-year growth. EBITDA increased 36.12% to Rs. 294.55 lakhs, while profit after tax grew 33.81% to Rs. 174.69 lakhs. The pharmaceutical company, focused on sales and marketing of medicines, attributed the performance to strategic initiatives including product portfolio expansion, strengthened marketing networks, and improved operational efficiency. Growth was achieved across both acute and chronic therapy segments through new product launches and enhanced field force productivity. Managing Director Tejash Hathi credited employee dedication and commitment to excellence for the strong results. The company's trading window for designated persons will open from November 13, 2025. IPO proceeds of Rs. 1,302 lakhs remain unutilized as of September 30, 2025.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
634.25
-
#1 -
-
-
-
-
65.56
19.00
-
#1 -
-
-
-
-
49.80
258.90
-
#1 -
-
-
-
-
28.55
6,750.00
-
#1 -
-
-
-
-
30.74
59.40
-
#1 -
-
-
-
-
48.58
479.20
-
#1 -
-
-
-
-
25.23
640.25
-
#1 -
-
-
-
-
37.48
979.10
-
#1 -
-
-
-
-
22.20
1,752.40
-
#1 -
-
-
-
-
38.65
964.80
-
#1 -
-
-
-
-
46.50
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Yearly Financial Results

Annual Financials
2023
2024
2025
TTM
Revenue
14
18
25
0
Expenses
13
16
20
0
EBITDA
1
2
5
0
Operating Profit %
4 %
9 %
20 %
0 %
Depreciation
0
0
0
0
Interest
0
0
1
0
Profit Before Tax
0
1
4
0
Tax
0
0
1
0
Net Profit
0
1
3
0
EPS in ₹
1.30
5.32
6.37
0.00

Balance Sheet

Balance Sheet
2023
2024
2025
Total Assets
6
10
22
Fixed Assets
1
1
1
Current Assets
6
8
20
Capital Work in Progress
0
0
0
Investments
0
0
0
Other Assets
6
9
21
Total Liabilities
6
10
22
Current Liabilities
3
4
12
Non Current Liabilities
2
4
3
Total Equity
1
2
7
Reserve & Surplus
1
2
2
Share Capital
0
0
5

Cash Flow

Cash Flow
2023
2024
2025
Net Cash Flow
0
0
4
Investing Activities
-0
-0
-1
Operating Activities
-0
-2
-2
Financing Activities
1
3
7

Share Holding

% Holding
Jun 2025
Sept 2025
Promoter
72.89 %
72.89 %
FIIs
10.03 %
10.03 %
DIIs
2.80 %
2.80 %
Government
0.00 %
0.00 %
Public / Retail
11.55 %
11.55 %
Others
2.74 %
2.74 %
No of Share Holders
9
9

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
10 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
10 Nov 2025 129.20 145.50

Technical Indicators